Distinguished by the lowest genetic complexity and the longest patient survival among NSCLC, ALK+ disease is serving as a model for the illustration of basic biological principles and for the development of novel therapeutic strategies, which will probably prove useful in other lung cancer subtypes and tumor entities as well. Here, ALK is linked to non-small cell lung carcinoma.